Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
Protease inhibitor
|
| gptkbp:approves |
gptkb:1996
gptkb:FDA |
| gptkbp:brand |
Norvir
|
| gptkbp:can_be_used_with |
gptkb:Atazanavir
gptkb:Lopinavir gptkb:Saquinavir |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:composed_of |
Chemical synthesis
|
| gptkbp:contraindication |
Severe liver disease
Hypersensitivity to ritonavir |
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| gptkbp:formulation |
gptkb:beer
Oral tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
Ritonavir
|
| gptkbp:indication |
Post-exposure prophylaxis
Prevention of HIV infection Prevention of mother-to-child transmission of HIV |
| gptkbp:ingredients |
C37 H48 N6 O5 S
|
| gptkbp:interacts_with |
CY P3 A4
CY P2 D6 |
| gptkbp:is_atype_of |
J05 A E02
|
| gptkbp:is_used_for |
HIV treatment
|
| gptkbp:lifespan |
3 to 5 hours
|
| gptkbp:manager |
Oral
|
| gptkbp:marketed_as |
Norvir
|
| gptkbp:name |
Essential Medicines
|
| gptkbp:pharmacokinetics |
Excreted in feces
Metabolized by CY P3 A4 Bioavailability 60-70% when taken with food Highly protein-bound Increases C D4 cell count Inhibits HIV protease Reduces viral load |
| gptkbp:provides_information_on |
Part of combination therapy
Used in ART (antiretroviral therapy) Used in PEP (post-exposure prophylaxis) Used in Pr EP (pre-exposure prophylaxis) |
| gptkbp:rounds |
Hepatic
|
| gptkbp:side_effect |
gptkb:Nausea
Diarrhea Fatigue Headache Abdominal pain Rash Hyperlipidemia Insulin resistance Liver enzyme elevation |
| gptkbp:storage |
Room temperature
|
| gptkbp:type_of |
155213-67-5
|
| gptkbp:bfsParent |
gptkb:Burroughs_Wellcome
|
| gptkbp:bfsLayer |
4
|